Repurposing the PD pipeline.
Atlas Bio's Parkinson's Disease analytical pipeline includes a 4-blend formulation strategy targeting NF-κB, mitochondrial function, gut-brain axis, and proteostasis. Multiple sclerosis shares mechanistic overlap with PD at the NF-κB and neuroinflammation axes. The MS study evaluates whether the PD blends transfer — under what mechanism-anchored modifiers, in what patient phenotype, and against what locked predictions.
From PD-derived to MS-targeted.
| Blend | Primary mechanism | Status |
|---|---|---|
| MS-IMM-01 | NF-κB modulation (lead candidate) | Phase IIa designed |
| MS-MITO-02 | Mitochondrial bioenergetics | Pre-clinical |
| MS-GUT-03 | Gut-brain axis / microbiome | Pre-clinical |
| MS-PROT-04 | Proteostasis / aggregate clearance | Pre-clinical |
Seven predictions, SHA-256 locked 2026-05-08.
- P1 — NF-κB modulation. Pre-specified target engagement biomarker movement.
- P2 — Cytokine profile. Pre-specified shift in IL-6, TNF-α, IFN-γ at week 12.
- P3 — T-cell repertoire. Pre-specified shift in Th17/Treg ratio.
- P4 — BBB permeability. Pre-specified imaging marker.
- P5 — Lesion burden. Pre-specified MRI gadolinium-enhancing lesion count delta.
- P6 — Relapse rate. Pre-specified annualized relapse rate change.
- P7 — Disability progression. Pre-specified EDSS slope change.
Phase IIa locked 2026-05-08. Subsequent phases (2–5) deferred pending phase IIa readout. The pre-registration is the falsification anchor — if the predictions are wrong, the data updates the framework, not the other way around.
The numeric thresholds, time-points, and statistical pre-specification for each prediction are gated. Gated
Phase IIa single-arm with risk-mitigation appendix.
Single-arm Phase IIa testing MS-IMM-01 in relapsing-remitting MS patients. Primary endpoint is the pre-specified cytokine shift (P2) at week 12; secondary endpoints include MRI lesion burden (P5) and patient-reported outcomes. Risk-mitigation appendix covers known PD-pipeline AEs that may surface in the MS population.
N, inclusion/exclusion criteria, dose escalation, and DSMB stopping rules are gated. Gated
Same stack, every indication.
- M2 · Pre-Registration — SHA-256 locking of P1–P7 before readout.
- M1 · IBC Reasoning — 19-agent audit of all seven predictions.
- M3 · Cross-Trial Validation — bridging from PD trial data to MS context with mechanism-anchored modifiers.
- M4 · RWE Pipelines — ClinicalTrials.gov, PubMed, FDA, EDGAR, and patient-reported feeds.
Want the locked-predictions document?
The abstract above is open. The full pre-registration — numeric prediction thresholds, blend formulations, dose escalation, DSMB rules, and the Phase IIa protocol — is available to verified clinicians, MS researchers, and sponsors under MNDA. The SHA-256 hash can be independently verified against the timestamped lock. Contact management to begin the access request.
Contact management →